Attorney’s Office for the District of Massachusetts. On August 30, 2022, after market hours, EyePoint disclosed that it had received a subpoena from the U.S. On this news, Cantaloupe stock fell $0.17 per share, or 4.6%, to close at $3.47 per share on September 29, 2022.įor more information on the Cantaloupe investigation go to: ĮyePoint Pharmaceuticals, Inc. This includes the design, implementation and operating effectiveness of information technology general controls in the areas of user access, change management and segregation of duties within various systems that support the Company's accounting and reporting processes, the design, implementation and operating effectiveness of controls over revenue and related accounts, and risk assessment and monitoring activities with respect to identifying and evaluating control deficiencies in a timely manner." On September 28, 2022, the company issued a report stating, "Based on progress made to date in the assessments of the effectiveness of internal controls over financial reporting, the Company currently expects to report three material weaknesses in its internal control framework. Additional information about each case can be found at the link provided.Ĭantaloupe, Inc. Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. (NASDAQ: SPPI), and F45 Training Holdings, Inc. (NASDAQ: EYPT), Spectrum Pharmaceuticals, Inc. (NASDAQ: CTLP, OTCMKTS: CTLPP), EyePoint Pharmaceuticals, Inc. 06, 2022 (GLOBE NEWSWIRE) - Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cantaloupe, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |